Important: Therapy notes
MHRA advice: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (June 2021) (www.gov.uk).
NICE Guidance: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019) (www.nice.org.uk).
Important: Formulation and dosage details
Concentrate solution for infusion 840mg/14mL (hospital use only)